MA34263B1 - Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) - Google Patents

Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Info

Publication number
MA34263B1
MA34263B1 MA35412A MA35412A MA34263B1 MA 34263 B1 MA34263 B1 MA 34263B1 MA 35412 A MA35412 A MA 35412A MA 35412 A MA35412 A MA 35412A MA 34263 B1 MA34263 B1 MA 34263B1
Authority
MA
Morocco
Prior art keywords
fxs
syndrome
markers useful
prediction markers
treating fragile
Prior art date
Application number
MA35412A
Other languages
English (en)
Inventor
Baltazar Gomez-Mancilla
Yunsheng He
Donald Johns
Joanne Meyer
Charles Paulding
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44121075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34263(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34263B1 publication Critical patent/MA34263B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de biomarqueurs pour déterminer la sensibilité d'un individu atteint du syndrome de l'X fragile (FXS) au traitement par un antagoniste de mGluR5.
MA35412A 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) MA34263B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33029910P 2010-04-30 2010-04-30
US37919710P 2010-09-01 2010-09-01
PCT/US2011/034244 WO2011137206A1 (fr) 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Publications (1)

Publication Number Publication Date
MA34263B1 true MA34263B1 (fr) 2013-05-02

Family

ID=44121075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35412A MA34263B1 (fr) 2010-04-30 2011-04-28 Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)

Country Status (22)

Country Link
US (1) US20130052644A1 (fr)
EP (1) EP2563934A1 (fr)
JP (1) JP2013524840A (fr)
KR (1) KR20130100906A (fr)
CN (1) CN102869791A (fr)
AU (1) AU2011245372A1 (fr)
BR (1) BR112012027816A2 (fr)
CA (1) CA2797854A1 (fr)
CL (1) CL2012003027A1 (fr)
EC (1) ECSP12012317A (fr)
GT (1) GT201200293A (fr)
IL (1) IL222534A0 (fr)
MA (1) MA34263B1 (fr)
MX (1) MX2012012615A (fr)
PE (1) PE20130213A1 (fr)
PH (1) PH12012502017A1 (fr)
RU (1) RU2012151273A (fr)
SG (1) SG184458A1 (fr)
TN (1) TN2012000485A1 (fr)
TW (1) TW201142293A (fr)
WO (1) WO2011137206A1 (fr)
ZA (1) ZA201207481B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2655326A1 (fr) * 2010-12-20 2013-10-30 Novartis AG Esters d'acides 4-(hétéro)aryl-éthynyl-octahydro-indole-1-carboxyliques
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013131981A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Marqueurs de prédiction utiles dans le diagnostic et le traitement du syndrome de l'x fragile (fxs)
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152600A2 (fr) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesure des taux de fmrp cellulaire pour le criblage d'un médicament à haut rendement et diagnostic du syndrome du x fragile
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
DK3058371T3 (da) 2013-10-14 2021-08-02 Univ Indiana Res & Tech Corp Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
EP4244631A4 (fr) * 2020-11-13 2024-10-30 Children's Hospital Medical Center Utilisations affinées de modulateurs du récepteur gabaa dans le traitement du syndrome de l'x fragile
EP4497436A4 (fr) * 2022-03-22 2025-08-06 Univ Kyoto Médicament thérapeutique ou prophylactique contre le syndrome de l'x fragile

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6143504A (en) * 1998-10-27 2000-11-07 Arch Development Corporation Methods and compositions for the diagnosis of fragile X syndrome
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
AR040847A1 (es) 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
JP4453297B2 (ja) 2003-05-27 2010-04-21 トヨタ自動車株式会社 車両用遊星歯車式多段変速機
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
US20090042195A1 (en) * 2005-10-07 2009-02-12 Bradford Coffee Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies
US7855053B2 (en) * 2006-07-19 2010-12-21 The Regents Of The University Of California Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region
BRPI0917564A2 (pt) 2008-08-04 2015-11-17 Novartis Ag bioensaio para proteína poli-q
US20100248239A1 (en) * 2009-03-24 2010-09-30 Mayo Foundation For Medical Education And Research Methods and materials for detecting fragile x mutations

Also Published As

Publication number Publication date
SG184458A1 (en) 2012-11-29
GT201200293A (es) 2014-06-09
TN2012000485A1 (en) 2014-04-01
CL2012003027A1 (es) 2014-02-14
PH12012502017A1 (en) 2013-01-21
EP2563934A1 (fr) 2013-03-06
MX2012012615A (es) 2012-12-17
KR20130100906A (ko) 2013-09-12
CN102869791A (zh) 2013-01-09
IL222534A0 (en) 2012-12-31
JP2013524840A (ja) 2013-06-20
ZA201207481B (en) 2013-06-26
RU2012151273A (ru) 2014-06-10
AU2011245372A1 (en) 2012-11-29
CA2797854A1 (fr) 2011-11-03
BR112012027816A2 (pt) 2017-08-08
WO2011137206A1 (fr) 2011-11-03
PE20130213A1 (es) 2013-03-19
TW201142293A (en) 2011-12-01
ECSP12012317A (es) 2013-01-31
US20130052644A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EP2350644A4 (fr) Semi-conducteur pour mesurer des interactions biologiques
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
EP2504702A4 (fr) Dispositifs de détection de composés à analyser
EP2652508A4 (fr) Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer
EP2817617A4 (fr) Dispositifs, méthodes et kits de test pour dosage d'analyte électronique
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
EP2563360A4 (fr) Biomarqueurs pour inhibiteurs de mdm2 destinés à être utilisés dans le traitement de maladies
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
EP2698381A4 (fr) Anticorps, trousse et méthode pour la détermination de peptides amyloïdes
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EP2437714A4 (fr) Procédés et systèmes pour surveiller l'utilisation d'un ascenseur
MA33323B1 (fr) Thérapie adjuvante de cancer
EA201291477A1 (ru) КОМБИНАЦИЯ СОЕДИНЕНИЙ GlyT1 С АНТИПСИХОТИЧЕСКИМИ СРЕДСТВАМИ
EP2542576A4 (fr) Procédés pour cribler des anticorps
EP2489207A4 (fr) Analyse multivoie pour traitement audio
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2621942A4 (fr) Agents fournissant des témoins et des étalons pour des tests d'immunoprécipitation
EP2596347A4 (fr) Laboratoire-sur-puce pour une analyse d'alcalinité
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
EP2630941A4 (fr) Dispositif pour déterminer si des patients sortent ou non du lit
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes